Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy

LANG, F. M., TERUYA, S., CUOMO, M., SANTOS, A. M., RADHAKRISHNAN, J., LENTZSCH, S., CHAKRABORTY, R., BHUTANI, D., & MAURER, M. S. (2024). Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.06.009
Authors:
Frederick M Lang
Sergio Teruya
Margaret Cuomo
Alfonsina Mirabal Santos
Jai Radhakrishnan
Suzanne Lentzsch
Rajshekhar Chakraborty
Divaya Bhutani
Mathew S Maurer
Affiliated Authors:
Frederick M Lang
Sergio Teruya
Margaret Cuomo
Alfonsina Mirabal Santos
Jai Radhakrishnan
Suzanne Lentzsch
Rajshekhar Chakraborty
Divaya Bhutani
Mathew S Maurer
Columbia Affiliation:
Author Keywords:
sglt2 inhibitor
cardiac amyloidosis
amyloid light-chain
heart failure
guideline-directed medical therapy
chronic kidney disease
elink
Publication Type:
Article
Unique ID:
10.1016/j.cardfail.2024.06.009
PMID:
38997000
DOI:
10.1016/j.cardfail.2024.06.009
Journal:
Journal of Cardiac Failure
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: